AVIR
Atea Pharmaceuticals, Inc.
NASDAQHealthcareBiotechnologyUS
Rating:C+
Company Profile
CEO
Jean-Pierre Sommadossi
IPO Date
2020-10-30
Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
Country
US
Atea Pharmaceuticals, Inc.
CEO
Jean-Pierre Sommadossi
IPO Date
2020-10-30
Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
Country
US
| 6,100 |
| $4.17 |
| 13 Mar 2026 | Corcoran Andrea | See Remarks | M-Exempt | Acquired | 60,000 | $1.24 |
| 13 Mar 2026 | Corcoran Andrea | See Remarks | M-Exempt | Acquired | 60,000 | $1.24 |
| 3 Feb 2026 | Horga Maria Arantxa | Chief Medical Officer | A-Award | Acquired | 173,500 | $4.24 |
| 3 Feb 2026 | Horga Maria Arantxa | Chief Medical Officer | M-Exempt | Disposed | 9,750 | $0.00 |
| 3 Feb 2026 | Horga Maria Arantxa | Chief Medical Officer | M-Exempt | Acquired | 51,283 | $0.00 |
| 3 Feb 2026 | Horga Maria Arantxa | Chief Medical Officer | F-InKind | Disposed | 16,073 | $4.24 |
| 3 Feb 2026 | Vavricka John | Chief Commercial Officer | F-InKind | Disposed | 11,570 | $4.24 |
| 3 Feb 2026 | Vavricka John | Chief Commercial Officer | M-Exempt | Disposed | 8,750 | $0.00 |